晚期肾透明细胞癌药物治疗进展  

Progress in systemic therapy for advanced clear cell renal cell carcinoma

作　　者：董良[1] 王伟英(审校)[1] DONG Liang;WANG Weiying(Department of Oncology,Shaoxing Hospital,China Medical University,Shaoxing,Zhejiang,312030,China)

机构地区：[1]中国医科大学绍兴医院肿瘤内科,浙江绍兴312030

出　　处：《临床泌尿外科杂志》2020年第9期758-763,共6页Journal of Clinical Urology

摘　　要：在过去的10多年里,晚期肾透明细胞癌的药物治疗取得了长足的进展。近年来,血管内皮生长因子抑制剂和免疫检测点抑制剂为晚期肾透明细胞癌患者带来的新的选择。不同药物联合方案是目前研究的热点。在本文中,我们讨论了这些治疗方案的疗效和安全性,为晚期肾透明细胞癌药物治疗方案的选择提供依据。The management of advanced clear cell renal cell carcinoma(RCC) has evolved over the past decade. Recently, the vascular endothelial growth factor(VEGF) inhibitors and immune checkpoint inhibitors became new options to the treatment armamentarium for advanced RCC. Therapies combining checkpoint inhibitors and VEGF inhibitors have been an area of intense investigation in recent years. In this review, we discuss the efficacy and safety results from the pivotal trials of these therapies to provide the basis for the choice of drug treatment regimen for advanced RCC.

关 键 词：肾透明细胞癌 联合治疗 免疫治疗 靶向治疗 

分 类 号：R737.11[医药卫生—肿瘤]